The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Wheeler, DC; Stefansson, BV; Batiushin, M; Bilchenko, O; Cherney, DZI; Chertow, GM; Douthat, W; Dwyer, JP; Escudero, E; Pecoits, R; Furuland, H; Gorriz, JL; Greene, T; Haller, H; Hou, FF; Kang, SW; Isidto, R; Khullar, D; Mark, PB; McMurray, JJV; Kashihara, N; Nowicki, M; Persson, F; Correa-Rotter, R; Rossing, P; Toto, RD; Umanath, K; Van Bui, P; Wittmann, I; Lindberg, M; Sjostrom, CD; Langkilde, AM; Heerspink, HJL

Heerspink, HJL (corresponding author), Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020; 35 (10): 1700

Abstract

Background. The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the ef......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索